Loading clinical trials...
Loading clinical trials...
A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFECTS OF LONG-ACTING SOMATOSTATIN (OCTREOTIDE LAR) THERAPY ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE TO SEVERE RENAL INSUFFICIENCY
Conditions
Interventions
Octreotide-LAR
Saline solution.
Locations
6
Italy
Ospedale San giovanni di Dio
Agrigento, AG, Italy
Clinical Research Center fo Rare Diseases Aldo and Cele Daccò
Ranica, Bergamo, Italy
Hospital "Vito Fazzi"
Lecce, Italy
Hospital "Ospedale Maggiore policlinico, Mangiagalli e Regina elena"
Milan, Italy
University "Federico II"
Naples, Italy
Ospedale Cà Foncello
Treviso, Italy
Start Date
May 1, 2011
Primary Completion Date
October 18, 2017
Completion Date
October 18, 2017
Last Updated
January 10, 2018
NCT07454174
NCT06065852
NCT03901521
NCT06594367
NCT06289998
NCT05190744
Lead Sponsor
Mario Negri Institute for Pharmacological Research
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions